Health Canada Clinical Evidence Guidance 2026: Medical Device Compliance Guide

Clinical Evidence Requirements for Class II, III & IV Medical Devices

Health Canada published its updated Guidance on clinical evidence requirements for medical devices on April 1, 2026. The guidance applies to Class II, III and IV medical devices and explains how manufacturers should approach clinical evidence for licensing, amendments and post-market activities. It reinforces that clinical evidence is a lifecycle responsibility, supporting a device from product development and pre-market review through post-market monitoring and evidence generation.

Clinical evidence can come from clinical investigations, published literature, comparator devices, clinical experience, real-world data and post-market information. The key question is not simply whether evidence exists, but whether it is relevant and sufficient to demonstrate the safety and effectiveness of the specific device for its intended use.

Scope: The guidance applies to Class II, III and IV medical devices and does not apply to in vitro diagnostic devices (IVDDs).

Why the 2026 Guidance Matters

Clinical evidence supports the clinical safety and effectiveness of a medical device. Health Canada's framework helps manufacturers determine:

• When clinical evidence may be required
• When device-specific clinical data may not be necessary
• How literature and comparator evidence can support a submission
• How real-world evidence can contribute
• How benefit, risk and uncertainty should be evaluated
• How patient diversity should be considered
• When additional evidence may be needed after licensing

Health Canada uses a risk-based, case-by-case approach, so evidence requirements can differ between devices even when technologies appear similar.

Clinical evidence planning should begin with:

Intended Use → Device Risk → Technology → Claims → Patient Population → Evidence Strategy

What Counts as Clinical Evidence?

Clinical evidence is information used to establish the clinical safety and effectiveness of a device for its intended purpose. Depending on the device, it may include:

• Device-specific clinical investigations
• Published clinical literature
• Comparator-device evidence
• Clinical experience
• Real-world data and real-world evidence
• Registries
• Post-market studies and surveillance information

The objective is not to collect the largest possible amount of data. Evidence should be:

Relevant → Reliable → Scientifically justified → Applicable to the device → Appropriate for the intended use → Sufficient to support safety and effectiveness

Manufacturers should also explain evidence limitations and uncertainties.

Class II, III and IV Devices

Clinical evidence expectations depend on device class, technology, risk, intended use and available evidence.

1. Class II Devices

A device-specific clinical investigation is not necessarily required for every Class II device. The need may be lower when technology and clinical performance are well established, testing adequately characterizes performance, changes are non-significant, and intended use and risks are well understood.

No clinical investigation does not mean no clinical justification. When device-specific data is not provided, the manufacturer should explain why existing evidence addresses safety, effectiveness, risks and intended use. Evidence needs may increase with novel technology, serious conditions, significant uncertainty, long-term use, rare adverse events or potentially different patient effects.

2. Class III Devices

Class III devices generally require a more comprehensive strategy covering intended use, claims, target population, risks, technology, clinical experience, comparator and literature evidence, device-specific data, RWE, uncertainty and overall benefit-risk.

Evidence from another device is not automatically applicable because devices appear similar. The manufacturer must demonstrate relevance to the subject device.

3. Class IV Devices

Class IV devices require particularly robust evidence planning because of their higher risk. Evidence should address clinical safety and effectiveness, intended purpose, relevant populations, claims, risks, long-term performance where applicable and overall benefit-risk.

Manufacturers should be able to explain:

• What evidence was considered and why
• How it applies to the subject device
• What uncertainties remain
• Why is the evidence sufficient for the proposed intended use

When Is Device-Specific Clinical Evidence Needed?

The need for device-specific clinical evidence depends on device characteristics, risk and the strength of existing evidence.

Factors that may increase the need for clinical data include:

• Novel technology or materials
• Limited clinical experience
• High or uncertain clinical risk
• Serious medical conditions
• Inconclusive literature
• Novel manufacturing processes
• Long duration of use
• Rare potential adverse events
• Limited evidence for the intended population
• Potential differences between patient subgroups
• Limited clinical benefit
• Inadequate comparator evidence

When existing evidence is used instead of a device-specific investigation, manufacturers should provide a clear scientific rationale explaining why it adequately addresses relevant safety and effectiveness questions.

Comparator Devices

Comparator devices can support a Canadian clinical evidence strategy when scientifically justified. Relevant factors include:

• Intended use and indications
• Design and technology
• Materials and biological characteristics
• Performance
• Patient population
• Risk profile
• Regulatory status

Similar names or the same broad purpose is not enough. The key question is whether similarities between the comparator and subject device are sufficient to make the clinical evidence applicable.

Health Canada generally expects comparator devices used in this context to be licensed in Canada. If a comparator is not licensed in Canada, manufacturers should provide objective evidence supporting its safety and effectiveness and a side-by-side comparison of relevant specifications.

Where differences exist, manufacturers should explain whether those differences could affect safety or effectiveness.

Published Literature

Published literature can form an important part of a clinical evidence package when it is relevant and critically evaluated. A literature strategy should consider:

• Device-specific publications and clinical studies
• Safety and effectiveness outcomes
• Patient populations and clinical endpoints
• Study quality and limitations
• Conflicting findings
• Applicability to the subject device
• Relevance to Canadian clinical practice

A large volume of literature does not necessarily mean strong evidence. Literature may be insufficient when it concerns a materially different device, indication, population or clinical outcome. Comparator literature also requires adequate comparability.

Real-World Evidence and Post-Market Data

Health Canada recognizes the potential value of real-world data (RWD) and real-world evidence (RWE). Relevant sources may include:

• Registries
• Electronic health records
• Clinical databases
• Post-market studies
• Long-term follow-up
• Device-specific clinical experience

RWE can be particularly useful for understanding rare adverse events, long-term outcomes, larger patient populations, under-represented subgroups, real-world patterns of use and performance outside controlled clinical studies.

Manufacturers must still demonstrate that RWD/RWE are relevant, reliable and applicable to the device under review. The specific device model, version and configuration represented in the data should also be understood.

Benefit-Risk and Uncertainty

Clinical evidence should be considered alongside expected clinical benefits and device risks. A clinical evaluation should address:

• Clinical benefits and magnitude of benefit
• Clinical risks and severity/probability of harm
• Evidence limitations and uncertainty
• Patient population
• Alternative treatment options
• Duration of use
• Long-term risks

Uncertainty may arise from small sample sizes, short follow-up, rare events, limited subgroup representation, limited long-term evidence, differences between study and marketed devices, limited Canadian experience or novel technology.

Manufacturers should not hide uncertainty. A strong clinical strategy explains:

What is known? → What is uncertain? → Why is the remaining uncertainty acceptable? → How will it be monitored or reduced?

Patient Diversity and SGBA Plus

The guidance highlights diverse patient populations through Sex and Gender-Based Analysis Plus (SGBA Plus). Relevant factors may include:

• Sex and gender
• Race and ethnicity
• Age
• Pregnancy and breastfeeding
• Disability
• Other relevant population characteristics

Manufacturers should consider whether safety or effectiveness could differ between populations and whether studies adequately represent intended users.

Where appropriate, manufacturers should consider population representation, stratification, subgroup analysis, disaggregated reporting and additional evidence for under-represented populations. If studies are not large enough to establish reliable subgroup conclusions, RWE and post-market experience may provide additional information.

This is particularly important for devices whose performance may depend on anatomy, physiology, body size, disease characteristics or other patient factors.

Clinical Evaluation

A clinical evaluation brings available evidence together into an overall assessment of the device. It should consider:

• Clinical investigations
• Published literature
• Comparator evidence
• Clinical experience
• Real-world evidence
• Safety and effectiveness
• Clinical claims
• Labelling, contraindications, warnings and precautions
• Instructions for use
• Benefit-risk and uncertainty

The evaluation should demonstrate that the device performs as intended and that its overall benefit-risk profile remains acceptable. Comparisons with established standards of care should be supported by objective evidence, including relevant limitations and uncertainty.

Clinical Evaluation Report (CER)

Manufacturers may provide a Clinical Evaluation Report (CER) with Class III or IV applications.

A CER presents the conclusions of the clinical evaluation and summarizes evidence supporting the device's intended purpose and benefit-risk profile.

A CER is not mandatory in Canada.

If submitted, a CER should be:

• Scientifically justified and device-specific
• Consistent with the license application and labelling
• Transparent about limitations and uncertainty
• Supported by appropriate evidence
• Clear about comparator information and Canadian regulatory status

Clinical Claims and Labelling

Clinical evidence should match what the manufacturer claims about the device. Manufacturers should verify that:

• Intended use and indications are supported
• Clinical claims are evidence-based
• Contraindications are appropriate
• Warnings reflect known risks
• Precautions are justified
• Instructions for use are consistent with the evidence

A useful framework is:

Intended Use → Indications → Claims → Clinical Evidence → Risk Management → Labelling

Claims should not extend beyond what the available clinical evidence can reasonably support.

Post-Market Clinical Evidence

Clinical evidence remains relevant after licensing. Health Canada may require additional clinical evidence where there is a reasonable belief that a licensed device may no longer meet applicable safety and effectiveness requirements.

Additional evidence may include follow-up of clinical investigations, post-market clinical studies, long-term safety/effectiveness data, RWE and post-market clinical experience.

Post-market evidence becomes particularly important when:

• Rare adverse events emerge
• Long-term outcomes remain uncertain
• New populations use the device
• Clinical use expands
• New indications are proposed
• Device modifications are introduced
• Real-world performance differs from clinical studies

Post-market evidence should therefore be considered during initial evidence planning rather than treated as a separate activity.

Clinical Evidence for Device Changes

Changes to an already licensed device may create new evidence requirements. Manufacturers should assess changes involving:

• Design, materials and software
• Inputs and components
• Intended purpose and indications
• Target population
• User environment or profile
• Hazards
• Duration of use
• Patient contact
• Number of applications

The key question is whether the change creates or increases a safety or effectiveness risk. Where non-clinical testing cannot adequately answer the relevant questions, additional literature or clinical evidence may be necessary.

Lifecycle Clinical Evidence Strategy

A practical lifecycle model is:

Evidence Planning → Pre-Market Evidence → Licensee Submission → Market Entry → Post-Market Monitoring → Additional Evidence → Benefit-Risk Reassessment

The strategy should connect:

• Clinical investigations
• Literature surveillance
• Complaints and incident reporting
• Post-market studies
• Registries and RWE
• Safety signal assessment
• Clinical claims review
• Regulatory intelligence

This approach helps manufacturers identify evidence gaps before they become regulatory problems.

Clinical Evidence Gap Assessment

Before a Canadian submission, manufacturers should complete a structured evidence gap assessment.

1. Define the Intended Use

Confirm intended purpose, indications, target population, users, use environment, duration of use and clinical claims.

2. Characterize the Device

Review technology, design, materials, components, software, accessories, biological characteristics and performance characteristics.

3. Map Existing Evidence

Identify device-specific data, literature, comparator evidence, RWD/RWE, clinical experience and post-market information.

4. Assess Evidence Quality

Evaluate relevance, reliability, applicability, completeness, consistency and limitations.

5. Identify Uncertainty

Document evidence gaps, population gaps, long-term uncertainties, safety uncertainties and effectiveness uncertainties.

6. Determine Additional Evidence Needs

Decide whether existing evidence is sufficient, additional clinical data are required, a clinical investigation is justified, additional RWE should be generated, or post-market evidence should be planned.

Health Canada Clinical Evidence Readiness Checklist

• Intended Use: Is the intended purpose clearly defined?
• Claims: Are clinical claims supported by evidence?
• Classification: Is device classification confirmed?
• Evidence: Is evidence relevant and sufficient?
• Comparator: Is comparator relevance justified?
• Literature: Has relevant literature been critically evaluated?
• Clinical Data: Are device-specific data sufficient where needed?
• Safety/Effectiveness: Are risks addressed and effectiveness demonstrated?
• Benefit-Risk: Is the overall profile favorable?
• Uncertainty: Are limitations clearly documented?
• Diversity: Are relevant populations represented?
• Labelling: Does labelling reflect the evidence?
• RWE: Has relevant real-world evidence been considered?
• Post-Market: Is additional evidence generation planned?
• Governance: Are responsibilities clearly assigned?

Common Mistakes to Avoid

Manufacturers should avoid:

• Assuming every Class II device requires a clinical investigation
• Assuming no clinical investigation means no clinical evidence is needed
• Treating comparator devices as automatically equivalent
• Using literature without assessing relevance and comparability
• Ignoring uncertainty or patient diversity
• Underrepresenting relevant populations
• Making claims beyond the evidence
• Separating clinical evidence from risk management
• Treating post-market evidence as an afterthought
• Using evidence from a materially different device without adequate justification

What Means for Manufacturers in 2026

The 2026 guidance points toward a more integrated approach to clinical evidence. Key trends include:

• Lifecycle evidence planning
• Greater use of real-world evidence
• Stronger benefit-risk assessment
• More explicit treatment of uncertainty
• Greater attention to diverse populations
• More structured comparator assessments
• Stronger integration of post-market evidence
• Better alignment between evidence and clinical claims
• Greater focus on long-term safety and effectiveness

For innovative medical devices, this approach is especially important because traditional clinical studies may not capture every aspect of real-world performance.

Recommended Clinical Evidence Workflow

1. Plan
Define intended use, claims, population and evidence requirements.

2. Map
Identify clinical data, literature, comparator evidence and RWE.

3. Assess
Evaluate relevance, quality, limitations, benefit-risk and uncertainty.

4. Identify Gaps
Determine whether additional evidence is required.

5. Generate
Conduct appropriate clinical investigations or other evidence-generation activities.

6. Integrate
Connect clinical evidence with risk management, labelling and regulatory documentation.

7. Submit
Prepare a clear, scientifically justified evidence package.

8. Monitor
Continue evaluating clinical performance after market entry.

9. Update
Generate additional evidence when device, clinical or regulatory circumstances require it.

Frequently Asked Questions

1. Does every Class II device require clinical data?

No. The need for device-specific clinical evidence depends on the device, technology, risk, intended use and available evidence. Where clinical data are not provided, manufacturers should have an appropriate scientific rationale.

2. Are Class III and IV devices subject to clinical evidence requirements?

Yes. The level and type of evidence depend on the specific device and its risk, intended use, claims and available supporting information.

3. Can comparator devices support a Canadian submission?

Yes. Comparator evidence can support a submission when scientific relevance and comparability are adequately established.

4. Can published literature be used?

Yes. Literature can support the evidence package when it is relevant, reliable and applicable to the subject device.

5. Is a Clinical Evaluation Report mandatory?

No. Health Canada states that a CER may be provided for Class III or IV applications, but it is not mandatory in Canada.

6. Does Health Canada consider patient diversity?

Yes. The guidance addresses SGBA Plus and considerations related to sex, gender, race, ethnicity, age and other relevant population characteristics.

7. Can RWE support medical device regulation?

Yes. Relevant and reliable real-world data can generate evidence that may contribute to regulatory decision-making.

8. Does clinical evidence end after licensing?

No. Additional clinical evidence may be required during the post-market phase where warranted.

9. What should manufacturers do now?

Manufacturers should review their intended use, claims, classification, evidence package, comparator strategy, patient populations, uncertainty, benefit-risk assessment and post-market evidence plan against the 2026 guidance.

How Maven Regulatory Solutions Can Help

Maven Regulatory Solutions supports medical device organizations with Canadian, U.S. and global regulatory requirements.

Our services include:

• Health Canada regulatory strategy
• Clinical evidence gaps assessments
• Clinical evidence planning
• Canadian medical device submissions
• Comparator evidence assessment
• Clinical literature evaluation
• Benefit-risk assessment support
• Clinical evaluation strategy
• Clinical investigation planning
• Real-world evidence strategy
• Post-market evidence planning
• Regulatory gap assessments
• Medical device compliance
• Lifecycle regulatory strategy
• Global regulatory support

We help manufacturers identify evidence gaps, strengthen regulatory strategies, prepare submission-ready documentation and develop practical lifecycle compliance programs.

Conclusion

Health Canada's April 2026 clinical evidence guidance reinforces an important principle:

Clinical evidence is a lifecycle responsibility not simply a pre-market submission exercise.

For Class II, III and IV medical device manufacturers, the objective should not be to generate the largest possible volume of clinical data.

The objective is to build the right evidence for the right device, intended use, patient population and risk profile.

That means connecting:

Clinical Evidence + Risk Management + Patient Diversity + Benefit-Risk + Real-World Evidence + Post-Market Surveillance

into one coherent strategy.

For manufacturers in 2026, the better question is therefore not:

“Do we have enough clinical evidence for our Canadian submission?”

It is:

“Is our clinical evidence strategy strong enough to demonstrate safety and effectiveness today and continue supporting the device throughout its lifecycle?”